The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
JAK2V617F mutation for the early diagnosis of Ph− myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis
Open accessAbstract
Recent studies suggested that JAK2V617F mutation is frequent in patients with splanchnic vein thrombosis (SVT) but not in patients with other venous thromboembolic events (VTE). However, whether screening for the JAK2V617F mutation in VTE patients is justified remains unclear. Therefore, we performed a systematic review to assess the frequency of JAK2 mutation in VTE patients and the role of JAK2V617F mutation in the diagnosis of myeloproliferative neoplasms. MEDLINE and EMBASE databases were searched. Two reviewers independently performed study selection and extracted study characteristics. Pooled odds ratios of case-control studies and weighted mean proportion of the prevalence of JAK2V617F mutation of uncontrolled series were calculated. Twenty-four studies involving 3123 patients were included. Mean prevalence of JAK2 mutation was 32.7% (95% confidence interval, 25.5%-35.9%) in SVT patients. JAK2 mutation was associated with increased risk of SVT (odds ratio, 53.98; 95% confidence interval, 13.10-222.45). Mean prevalence of JAK2 mutation in other VTE patients was low (range, 0.88%-2.57%). Presence of JAK2V617F mutation in SVT patients was associated with a subsequent diagnosis of myeloproliferative neoplasm in many patients. JAK2 mutation is strongly associated with SVT, and routine screening of JAK2 mutation appears to be indicated in these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A meta-analysis reported a JAK2 mutationprevalenceof32.7%(95%CI25.5 e 35.9%)inpatients with AMVT compared with approximately 1% in patients with VTEinothersites, and found a strong association between JAK2 mutation and MVT (OR 53.9, 95% CI 13.1 e 222.5). 214”
In the citing paper
“A meta-analysis reported a JAK2 mutationprevalenceof32.7%(95%CI25.5 e 35.9%)inpatients with AMVT compared with approximately 1% in patients with VTEinothersites, and found a strong association between JAK2 mutation and MVT (OR 53.9, 95% CI 13.1 e 222.5). 214”
In the citing paper
“The JAK2 mutation is diagnostic of myeloproliferative diseases and appears to be linked to the development of AMVT.”
In the citing paper
“Moreover, 52% (95% CI 38 e 67%) of patients with MVT and JAK2 mutation were diagnosed with a myeloproliferative disease during follow up, with MVT being the first manifestation of the underlying condition. 214”
In the citing paper
“AMVT is a common first clinical manifestation in patients with newly diagnosed myeloproliferative diseases such as polycythemia vera or essential thrombocytosis.”
In the citing paper
“A meta-analysis reported a JAK2 mutationprevalenceof32.7%(95%CI25.5 e 35.9%)inpatients with AMVT compared with approximately 1% in patients with VTEinothersites, and found a strong association between JAK2 mutation and MVT (OR 53.9, 95% CI 13.1 e 222.5). 214”
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Investigating and dealing with publication and other biases in meta-analysis
Sterne, J. A. C., Egger, M., & Smith, G. D. (2001) · BMJ · doi:10.1136/bmj.323.7304.101 · Cited by 2,225
Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H., Barbui, T., Hanson, C., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., et al. (2007) · Blood · doi:10.1182/blood-2007-04-083501 · Cited by 919
Campbell, P. J., Scott, L. M., Buck, G. A. N., Wheatley, K., East, C. L., Marsden, J. T., Duffy, A. M., Boyd, E. M., Bench, A. J., Scott, M. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67785-9 · Cited by 651
Polycythemia Vera: The Natural History of 1213 Patients Followed for 20 Years
Policitemia, G. I. S. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-9-199511010-00003 · Cited by 507
Cited by
Sorted by citations
Items 101–176 of 176
Advances in understanding and management of polycythemia vera
Vannucchi, A. M., & Guglielmelli, P. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833ed81c · Cited by 11
Current approaches to challenging scenarios in myeloproliferative neoplasms
Zimran, E., Hoffman, R., & Kremyanskaya, M. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1457441 · Cited by 11
Venous thrombosis at unusual site in women
Romualdi, E., & Ageno, W. (2011) · Thrombosis Research · doi:10.1016/s0049-3848(11)70023-8 · Cited by 11
Self-citationThrombotic Venous Diseases of the Liver
Sabol, T. P., Molina, M., & Wu, G. Y. (2015) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2015.00014 · Cited by 11
Chatzidavid, S., Giannakopoulou, N., Diamantopoulos, P. T., Gavriilaki, E., Katsiampoura, P., Lakiotaki, E., Sakellariou, S., Viniou, N., & Dryllis, G. (2021) · Thrombosis Journal · doi:10.1186/s12959-021-00269-8 · Cited by 10
Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia
Iványi, J. L., Márton, É., & Plander, M. (2011) · Orvosi Hetilap · doi:10.1556/oh.2011.29226 · Cited by 10
Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source
Trifan, G., Shafi, N., & Testai, F. D. (2018) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2018.05.052 · Cited by 10
How I manage myeloproliferative neoplasm‐unclassifiable: Practical approaches for 2022 and beyond
McLornan, D. P., Hargreaves, R., Hernández‐Boluda, J. C., & Harrison, C. N. (2022) · British Journal of Haematology · doi:10.1111/bjh.18087 · Cited by 9
Current challenges in the management of essential thrombocythemia.
Kleman, A., Singavi, A. K., & Michaelis, L. C. (2017) · PubMed · Cited by 9
Hemichorea in a patient with JAK2V617F blood cells
Lew, J., Frucht, S. J., Kremyanskaya, M., Hoffman, R., & Mascarenhas, J. O. (2013) · Blood · doi:10.1182/blood-2012-12-468751 · Cited by 9
Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms
Guglielmelli, P., & Vannucchi, A. M. (2010) · F1000 Medicine Reports · doi:10.3410/m2-16 · Cited by 8
Morsia, E., Torre, E., Martini, F., Morè, S., Poloni, A., Olivieri, A., & Rupoli, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031524 · Cited by 8
Orion, D., Itsekson-Hayosh, Z., Peretz, S., Mendel, R., Yaniv, G., Attia, M., & Merkel, D. G. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.783795 · Cited by 8
JAK2 V617F Mutation Is Not Associated with Thrombosis in Behcet Syndrome
Ar, M. C., Hatemi, G., Ekizoğlu, S., Bilgen, H., Sacli, F. S., Buyru, A. N., Soysal, T., Ülkü, B., & Yazıcı, H. (2011) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029611427440 · Cited by 8
Myeloproliferative neoplasms in adolescents and young adults
Amerikanou, R., Lambert, J., & Alimam, S. (2022) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2022.101374 · Cited by 7
Link, C. S., Platzbecker, U., Kroschinsky, F., Pannach, S., Thiede, C., Platzek, I., Ehninger, G., & Schuler, M. K. (2013) · Case Reports in Oncology · doi:10.1159/000352088 · Cited by 7
Thrombosis in Myeloproliferative Neoplasms With JAK2V617F Mutation
Sun, T., & Zhang, L. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612453761 · Cited by 7
JAK2 V617F mutation, mesenteric vein thrombosis, and myeloproliferative disorders
Owens, C. D. (2010) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2010.01.097 · Cited by 7
Bleeding and Thrombosis in Hematologic Neoplasia
Shatzel, J. J., Scherber, R. M., & DeLoughery, T. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_59 · Cited by 8
Scandellari, R., Vettore, S., Scapin, M., Bizzaro, N., Randi, M. L., & Fabris, F. M. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-01-0041 · Cited by 6
Biagioni, E., Pedrazzi, P., Marietta, M., Benedetto, F. D., Villa, E., Luppi, M., & Girardis, M. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0832-5 · Cited by 6
Jacobs, J. W., Sharma, D., & Vnencak‐Jones, C. L. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02525-0 · Cited by 6
Low prevalence of JAK2 V617F mutation in patients with first unprovoked venous thromboembolism
Rodger, M. A., Kekre, N. K., Gal, G. L., Kahn, S. R., Wells, P. S., Anderson, D. A., Chagnon, I., Solymoss, S., Crowther, M. A., Perrier, A., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08701.x · Cited by 6
Self-citationPrevalence of the JAK2 V617F and MPL Mutations in Stroke, Abdominal and Peripheral Venous Thrombosis
McCarthy, N., McCarron, S. L., & Langabeer, S. E. (2010) · Acta Haematologica · doi:10.1159/000320171 · Cited by 6
Sugimoto, Y., Nagaharu, K., Ohya, E., Ohishi, K., Tawara, I., Ito, T., Gotoh, A., Nakamae, M., Kimura, F., Koike, M., et al. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03862-5 · Cited by 5
Chia, Y. C., Ramli, M., Woon, P. Y., Johan, M. F., Hassan, R., & Islam, M. A. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.01.002 · Cited by 5
RetractedGenetic Risk Factors of Venous Thromboembolism in the East Algerian Population
Moussaoui, S., Saussoy, P., Ambroise, J., Defour, J., Zouitene, R., Sifi, K., & Abadi, N. (2015) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615600789 · Cited by 5
Do we need more guidance on thrombophilia testing? Challenges and special considerations
Marongiu, F., Ruberto, M. F., Marongiu, S., Mameli, A., & Barcellona, D. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2306821 · Cited by 5
Risk of recurrence of unusual site venous thromboembolism
Riva, N., Dentali, F., Donadini, M. P., Squizzato, A., & Ageno, W. (2013) · Hämostaseologie · doi:10.5482/hamo-13-03-0006 · Cited by 5
Self-citationThe Role of JAK2 Mutation in Thrombotic Complications of Chronic Myeloproliferative Neoplasms
Popov, V. M., Onisâi, M., Găman, M., & Vlădăreanu, A. M. (2014) · EMJ Hematology · doi:10.33590/emjhematol/10311605 · Cited by 5
Cooke, T., Soderquist, C. R., MANSUKHANI, M. M., & Hsiao, S. J. (2025) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaf197 · Cited by 4
JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis
Salhotra, A., & Oo, T. H. (2012) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-012-0215-2 · Cited by 4
Novel Risk Factors for Venous Thromboembolism
Squizzato, A., Brivio, L., Appio, L., & Dentali, F. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.05.007 · Cited by 4
Self-citationSant’Antonio, E., Borsani, O., Camerini, C., Botta, C., Santoro, M., Allegra, A., & Siragusa, S. M. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100903 · Cited by 4
Portal vein thrombosis due to essential thrombocythemia with limited cutaneous systemic sclerosis
Iwaki, K., Ueda, Y., Mishima, M., Narukami, S., Shiokawa, M., Sawada, K., Kanda, J., Takahashi, K., & Seno, H. (2020) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-020-01274-6 · Cited by 4
Genetic insights into myeloproliferative neoplasms and unusual sites thrombosis
Morsia, E., Ranalli, P., Baldoni, S., Mancini, S., Morè, S., Cantò, C., Lame, D., Barba, G. L., Poloni, A., Rupoli, S., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06606-5 · Cited by 3
Portal Vein Thrombosis Secondary to Occult Polycythemia Vera
Gameiro, A. F., Nunes, A. R., Guerra, P. G., Mateus, E., & Fernandes, F. (2020) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2020_002003 · Cited by 3
Quel bilan étiologique réaliser au décours d’une EP/TVP ?
Benhamou, Y., Delluc, A., Mauge, L., Fischer, A., & Sanchez, O. (2021) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2019.05.008 · Cited by 4
Reda, S., Chang, J., Busse, J., Schwarz, N., McRae, H. L., Müller, J., Strassburg, C. P., Oldenburg, J., Pötzsch, B., Jansen, C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010292 · Cited by 3
Les thromboses veineuses splanchniques : étude monocentrique de 31 cas
Benjilali, L., & Essaadouni, L. (2015) · Journal des Maladies Vasculaires · doi:10.1016/j.jmv.2015.12.001 · Cited by 3
Portal vein thrombosis – experience in a single centre
Swallow, G., & Pavord, S. R. (2012) · British Journal of Haematology · doi:10.1111/bjh.12037 · Cited by 2
Delayed diagnosis of polycythaemia vera in an adult female with non-cirrhotic portal hypertension
Tachi, K., Ekem, V., & Dei‐Adomakoh, Y. (2022) · Ghana Medical Journal · doi:10.4314/gmj.v56i1.6 · Cited by 2
Alkhaldy, H. Y. M., Yahya, A., Algarni, A. M., Bakheet, O. S. E., Assiri, M., & Saboor, M. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s480705 · Cited by 2
JAK2 46/1 haplotype seems not to be associated with lower limb deep venous thrombosis.
Trifa, A., Criṣan, S., Popp, R., Cucuianu, A., & Buzoianu, A. (2010) · Blood Cells, Molecules & Diseases · doi:10.1016/j.bcmd.2010.07.004 · Cited by 2
Ishibashi, H., Adachi, S., Katakura, Y., Fukita, Y., Itobayashi, E., & Yokosuka, O. (2014) · Kanzo · doi:10.2957/kanzo.55.170 · Cited by 2
Bleeding and Thrombosis in Hematologic Neoplasia
Ciszewski, A., & DeLoughery, T. G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_61 · Cited by 2
Goodyer, M. J., Langabeer, S. E., Haslam, K., & Murphy, K. (2015) · Pathology & Oncology Research · doi:10.1007/s12253-015-9994-8 · Cited by 2
Venous Thromboembolism in Unusual Locations
Afzal, A., Conyers, F. G., Sauk, S. C., & Schaefer, J. K. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.01.007 · Cited by 1
Unmet clinical needs in the management of patients with splanchnic vein thrombosis
Riva, N., Rancan, E., Ageno, W., & Dentali, F. (2010) · Internal and Emergency Medicine · doi:10.1007/s11739-010-0473-7 · Cited by 1
Self-citationSyndrome de Budd-Chiari primitif
Rautou, P., Plessier, A., Condat, B., & Valla, D. C. (2010) · Sang thrombose vaisseaux · doi:10.1684/stv.2010.0477 · Cited by 1
Risk and Prognostic Factors in Cerebral Venous Thrombosis
Kostal, M., Krajíčková, D., Ivanova, E. Y., Gabalec, F., Vrbacký, F., Sadílek, P., & Dulicek, P. (2017) · Journal of Hematology & Thromboembolic Diseases · doi:10.4172/2329-8790.1000278 · Cited by 1
Hepatic vein thrombosis and PVT: A personal view on the contemporary development of ideas
Valla, D. C. (2024) · Clinical Liver Disease · doi:10.1097/cld.0000000000000246 · Cited by 1
Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016
Elalamy, I., & Falanga, A. (2018) · Cancer Investigation · doi:10.1080/07357907.2018.1425698 · Cited by 1
Budd–Chiari Syndrome and Myeloproliferative Neoplasms
Stefano, V. D., & Rossi, E. (2019) · Springer eBooks · doi:10.1007/978-981-32-9232-1_6 · Cited by 1
Management of Portal and Mesenteric Venous Thrombosis
Turkeltaub, J. A., & Kriss, M. S. (2020) · Digestive Disease Interventions · doi:10.1055/s-0040-1712119 · Cited by 1
Myeloproliferative Neoplasms: Thrombosis and Hemorrhage
Reeves, B., & Moll, S. (2016) · doi:10.1002/9781118344729.ch15 · Cited by 1
Riva, N., Donadini, M. P., Dentali, F., Squizzato, A., & Ageno, W. (2012) · Phlebologie · doi:10.1055/s-0037-1621810
Self-citationTROMBOSE DE VEIA PORTA EM CRIANÇAS E ADOLESCENTES: casuística e trombofilias associadas
Liu, P. M. F. (2011) · Americanae (AECID Library)
Green, D. (2009) · Journal watch · doi:10.1056/oh200907070000001
Diagnostik und Therapie der Polycythaemia vera im Jahre 2015
Lengfelder, E., Grießhammer, M., & Koschmieder, S. (2015) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0041-103336
Myeloproliferative neoplasms and splanchnic vein thrombosis
Barosi, G., & Rosti, V. (2015) · doi:10.2217/fmeb2014.14.17
Ram, R., & Kuban, J. D. (2018) · Springer eBooks · doi:10.1007/978-3-319-62088-6_11
Accurso, V., Santoro, M., Contrino, A. D., Casimiro, P., Raso, S., Carlisi, M., Sardo, M., Perez, A., Di Piazza, F., Russo, A., et al. (2019) · Journal of Hematology and Clinical Research · doi:10.29328/journal.jhcr.1001012
Portal vein thrombosis in a child with essential thrombocythemia seven years after diagnosis
Chatterjee, G., & Yadav, S. P. (2019) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2019.1665153
Scamuffa, M. C., Latagliata, R., Bizzoni, L., Luca, M. L. D., Falco, F., & Ranieri, S. C. (2020) · Journal of Case Reports · doi:10.17659/01.2020.0016
Thromboses inhabituelles et syndrome catastrophique des antiphospholipides
Lanéelle, D., Urbanski, G., Beucher, A., & Lavigne, C. (2013) · Réanimation · doi:10.1007/s13546-013-0716-5
Treatment Algorithm of Essential Thrombocythemia
O’Sullivan, J., Green, A. C., & Harrison, C. N. (2023) · Springer eBooks · doi:10.1007/978-981-99-3810-0_38
The Pattern of Thrombosis in Patients with JAK2 V617F Mutation
Akoum, R. (2023) · Journal of Blood Disorders · doi:10.26420/jblooddisordl.2023.1072
Thida, A. M., Luhrs, C. A., Baral, A., Li, Z., & Brown, J. (2025) · Cureus · doi:10.7759/cureus.85208
Leban, M., Kavčič, M., Peterlin, J., Jazbec, J., & Kotnik, B. F. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1729489
Woodley, C., & Sriskandarajah, P. (2026) · Cancers · doi:10.3390/cancers18050728
Bourrienne, M. (2023) · theses.fr (ABES) · doi:10.70675/d0594ae8z342ez443az8ec7z19db6dbc94e6
Genomic profiling for thrombosis risk prediction in myeloproliferative neoplasms
Mantha, S. H. (2026) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2026.451
Ağalar, C., & Kerem, M. (2026) · Springer eBooks · doi:10.1007/978-3-032-15076-9_21
Haaris, S. M., Musani, S. H., & Sethi, S. M. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02439-z
Amadore, R. A., Anopol, J. A., & Gauiran, D. T. V. (2026) · BMJ Case Reports · doi:10.1136/bcr-2026-276448
Metadata
- Authors
- Dentali, F., Squizzato, A., Brivio, L., Appio, L., Campiotti, L., Crowther, M., Grandi, A. M., & Ageno, W.
- Affiliations
- University of Insubria (IT)
- McMaster University (CA)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-05-28
- Volume
- 113
- Issue
- 22
- Pages
- 5617-5623
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2000782581
- Cited by
- 176
- References
- 60
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 9 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 12 · 2019: 7 · 2018: 6 · 2017: 10 · 2016: 8 · 2015: 12 · 2014: 12 · 2013: 13 · 2012: 18
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- JAK2 V617F mutation, myeloproliferative neoplasms, venous thromboembolism, splanchnic vein thrombosis, mutation detection, early diagnosis, prevalence
- MeSH terms
- Algorithms, Female, Gene Frequency, Humans, Male, Myeloproliferative Disorders, Neoplasms, Phenylalanine, Philadelphia Chromosome, Biomarkers, Tumor, Valine, Case-Control Studies, Point Mutation, Amino Acid Substitution, Janus Kinase 2, Venous Thromboembolism, Early Detection of Cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
